A Study in Participants With Moderate to Severe Psoriasis
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose for this study is to help answer the following research questions
- The safety of ixekizumab (LY2439821) and any side effects that might be associated with
it.
- Whether ixekizumab can help participants with Psoriasis.
- How much ixekizumab should be given to participants.